Janet Huffman

Interim Chief Executive Officer & Chief Financial Officer

Ms. Huffman served as Chief Financial Officer for TRxADE HEALTH, Inc., a Nasdaq-listed company focused on health services IT for retail pharmacies. In 2019, Ms. Huffman was a founding member of Banyan Pediatric Care Centers and served as its Chief Financial Officer. After leading Banyan’s merger with Assisted 4 Living, Inc., an OTC-listed company later renamed Arboreta Healthcare Inc. and a provider of skilled nursing, rehabilitation and assisted living services, she continued as Chief Financial Officer until February 2022. Prior to Arboreta Healthcare, Ms. Huffman was the Chief Financial Officer for Signature HomeNow, a home healthcare services company. Earlier in her career, she served as Director of Finance and Regional Director of Operations for Infinity Homecare and was Vice President of Finance for Family Home Health Services.

Ms. Huffman obtained a Bachelor’s degree in accounting and a Master’s degree in accounting, both from the University of South Florida.

Christine M. Farrell

Financial Consultant

Christine M. Farrell joined Odyssey in April 2019 as a financial consultant serving as our Controller and Secretary and became Chief Financial Officer and Secretary in January 2021. From February 1997 to 2014, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc., a medical device company specializing in unique drug delivery technologies. Prior to joining Bioject, Ms. Farrell held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. degree in Accounting from the University of Washington and an M.B.A. from Willamette University in Salem, Oregon.

Greg Gironda

Head of Business Development

Mr. Gironda is a seasoned lifesciences executive with 30 plus years of experience and a distinguished track record in business development, strategic planning, and commercialization within the pharmaceutical and biotechnology sectors. With expertise spanning in/out-licensing, M&A transactions, and alliance management, he has been successful in raising capital to fund acquisitions and fuel business growth while leading numerous high-impact partnerships. Gregory has played a pivotal role in advancing dozens of pharmaceutical and biotech products from conception to commercialization while driving revenue growth through innovative strategies. He has held leadership positions at industry-leading companies, including King Pharmaceuticals, EMD Serono, Neura Therapeutik, GSK, and Genentech. Currently serving as head of Business Development at Oragenics, he continues to drive operational excellence and business expansion. Gregory holds a B.S. in Business Management from the University of Tampa.

James P. Kelly, MA, MD, FAAN, FANA

Chief Medical Officer

Dr. Kelly is the Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, CO. The MIBH is a specialized treatment program funded by the Marcus Foundation to care for US military Veterans with persistent symptoms of TBI. He is also National Director of the Gary Sinise Foundation Avalon Network TBI Medical Programs for which the MIBH serves as the clinical coordinating center.

His immediate past position was Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center in Bethesda, MD. As its founding Director, he led the creation of an innovative interdisciplinary team of healthcare professionals who blended high-tech diagnosis and treatment with complementary and alternative medical interventions in a holistic, integrative approach to the care of U.S. military personnel with the complex combination of TBI and psychological conditions such as post-traumatic stress, depression, and anxiety. In this role, Dr. Kelly was frequently called upon by leaders of the Military Health System in the Pentagon, the U.S. Congress, the Department of Veterans Affairs, and numerous military facilities in the continental U.S. and abroad. He twice traveled to Afghanistan to advise and assist at military hospital programs and forward operating base medical units.

William “Frank” Peacock MD

Chief Clinical Officer

Dr. Peacock is currently the Vice Chair for Emergency Medicine Research at Baylor College of Medicine and a past Professor at the Cleveland Clinic Lerner College of Medicine. He is also the Principal Investigator of a trial for a company developing blood biomarkers for the identification of concussion in the emergency department, which is analyzing acute blood markers that are elevated after concussion to not only ensure concussion is identified but also as a predictor of potential severity and longer-term complications. Dr. Peacock is a world-renowned speaker and researcher. He has been instrumental in the approval and use of high sensitivity blood troponins for acute coronary syndrome failure in emergency settings, which can be seen in the JAMA Cardiology publication, Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients with Possible Acute Coronary Syndrome, and he is the editor of the first book of “Biomarkers of Traumatic Brain Injury”.